Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: Clinical and correlative results

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 2, 2014, Pages 107-113

  Ruan, Jia ^a   Gregory, Stephanie A ^b   Christos, Paul ^a   Martin, Peter ^a   Furman, Richard R ^a   Coleman, Morton ^a   Leonard, John P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Anti VEGF; Chemotherapy; Mantle cell lymphoma; Tumor microenvironment

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EDEMA; ENDOTHELIAL PROGENITOR CELL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; INFECTION; INFUSION RELATED REACTION; LONG TERM CARE; MALE; MANTLE CELL LYMPHOMA; MIDDLE AGED; MOUTH DISEASE; MOUTH SORE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEINURIA; SECOND CANCER; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEART LEFT VENTRICLE FUNCTION; KAPLAN MEIER METHOD; LYMPHOMA, MANTLE-CELL; MULTICENTER STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; AGED; ANEMIA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; FATIGUE; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PREDNISONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VENTRICULAR DYSFUNCTION, LEFT; VINCRISTINE;

EID: 84896395732     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.10.002     Document Type: Article

References (16)

1. A. Herrmann, E. Hoster, and T. Zwingers et al. Improvement of overall survival in advanced stage mantle cell lymphoma J Clin Oncol 27 2009 511 518.
2. O.M. Howard, J.G. Gribben, and D.S. Neuberg et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival J Clin Oncol 20 2002 1288 1294.
3. G. Lenz, M. Dreyling, and E. Hoster et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) J Clin Oncol 23 2005 1984 1992.
4. J.E. Romaguera, L. Fayad, and M.A. Rodriguez et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine J Clin Oncol 23 2005 7013 7023.
5. M. Dreyling, G. Lenz, and E. Hoster et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL networks Blood 105 2005 2677 2684.
6. J. Ruan, K. Hajjar, S. Rafii, and J.P. Leonard Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma Ann Oncol 20 2009 413 424.
7. N. Ferrara, K.J. Hillan, H.P. Gerber, and W. Novotny Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 2004 391 400.
8. N. Ferrara, and R.S. Kerbel Angiogenesis as a therapeutic target Nature 438 2005 967 974.
9. A.T. Stopeck, J.M. Unger, and L.M. Rimsza et al. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest Oncology Group study S0108 Leuk Lymphoma 50 2009 728 735.
10. K.N. Ganjoo, C.S. An, and M.J. Robertson et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis Leuk Lymphoma 47 2006 998 1005.
11. A.T. Stopeck, J.M. Unger, and L.M. Rimsza et al. A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515 Blood 120 2012 1210 1217.
12. J.F. Seymour, M. Pfreundshuh, B. Coiffier, M. Trneny, L.H. Sehn, and E. Csinady The addition of bevacizumab to standard therapy with R-CHOP in patients with previously untreated diffuse large B-cell lymphoma is associated with an increased rate of cardiac adverse events: final analysis of safety and efficacy outcomes from the placebo-controlled phase 3 MAIN study ASH Annual Meeting Abstracts 120 2012 (Abstract 58).
13. B.D. Cheson, S.J. Horning, and B. Coiffier et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas J Clin Oncol 17 1999 1244 1253.
14. R.H. Advani, F. Hong, and K.N. Ganjoo et al. Cardiac toxicity associated with the anti-VEGF monoclonal antibody bevacizumab (Avastin) in combination with CHOP (A-CHOP) chemotherapy for peripheral T cell lymphoma (PTCL): the ECOG 2404 Trial ASH Annual Meeting Abstracts 114 2009 (Abstract 1671).
15. J. Ruan, P. Martin, and M. Coleman et al. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma Cancer 116 2010 2655 2664.
16. R. Fragoso, T. Pereira, Y. Wu, Z. Zhu, J. Cabecadas, and S. Dias VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease Blood 107 2006 1608 1616